Avoid common mistakes on your manuscript.
Correction to: Dermatol Ther (Heidelb) https://doi.org/10.1007/s13555-023-01058-z
Authors would like to correct the Error in Fig. 1, which should illustrate that the study arms were compared in the study. As reflected in the text, these are the Q2W arm from the SOLO-CONTINUE study and the Q4W arms from the ADvocate trial. However, the gold border for the ADvocate trials is erroneously placed around the Q2W arms. The revised version of Fig. 1 is updated here.
The revised version of Table 1 is updated here.
Affiliation of authors Kim Rand and Juan Manuel Ramos-Gon updated from ‘Health B.V’ to ‘Maths in Health B.V’.
![figure 1](http://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs13555-023-01076-x/MediaObjects/13555_2023_1076_Fig1_HTML.png)
ADvocate and SOLO-CONTINUE trial designs. The arms used in this study are outlined in gold
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Rand, K., Ramos-Goñi, J.M., Akmaz, B. et al. Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb) 14, 183–185 (2024). https://doi.org/10.1007/s13555-023-01076-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13555-023-01076-x